KELLEY RUNDE: Open Payments
NPI 1942993894 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$824 in 52 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $106 · 2025 $824
Food & beverage: $824
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $259 |
| Otsuka America Pharmaceutical, Inc. | 13 | $150 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $88 |
| Alkermes, Inc. | 3 | $71 |
| E.R. Squibb & Sons, L.L.C. | 2 | $53 |
| Neurocrine BioSciences, Inc. | 3 | $48 |
| Janssen Pharmaceuticals, Inc | 2 | $32 |
| Vertical Pharmaceuticals, LLC | 1 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
Products named: VRAYLAR, REXULTI, CAPLYTA, ARISTADA, COBENFY, INGREZZA, SPRAVATO, Relexxii.
Industry payments across MO — which companies pay providers there.
